<SEC-DOCUMENT>0000950170-21-001784.txt : 20210913
<SEC-HEADER>0000950170-21-001784.hdr.sgml : 20210913
<ACCEPTANCE-DATETIME>20210913160434
ACCESSION NUMBER:		0000950170-21-001784
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210913
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210913
DATE AS OF CHANGE:		20210913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eliem Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001768446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				832273741
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40708
		FILM NUMBER:		211249659

	BUSINESS ADDRESS:	
		STREET 1:		23515 NE NOVELTY HILL ROAD
		STREET 2:		SUITE B221 #125
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98053
		BUSINESS PHONE:		425-276-2300

	MAIL ADDRESS:	
		STREET 1:		23515 NE NOVELTY HILL ROAD
		STREET 2:		SUITE B221 #125
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98053
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>elym-20210913.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-09-13T15:44:06.6990+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:elym="http://eliemtx.com/20210913" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_27e25d99-be92-4dc7-9c77-44581593cbf9" name="dei:AmendmentFlag" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de">false</ix:nonNumeric><ix:nonNumeric id="F_9a430ee6-ce96-4916-93b6-c113941c6753" name="dei:EntityCentralIndexKey" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de">0001768446</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="elym-20210913.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-13</xbrli:startDate><xbrli:endDate>2021-09-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(68,84,106,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:Times New Roman;">	</span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WASHINGTON, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f934b99-6349-40f2-94eb-1dd31b785337" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">8-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CURRENT REPORT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf732ab5-fd0b-48b6-884f-9b74b21d832b" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">September 13, 2021</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9b66dc7-db83-4515-ad19-d51c46661da2" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">ELIEM THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_829671a8-9a9a-4ebc-bcd5-1474891a374f" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15f0b219-e4ba-43a9-9517-f720f4783543" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-40708</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01adacdc-9e5a-4233-b110-6d707e674228" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">83-2273741</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(State or Other Jurisdiction</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(IRS Employer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e97fb51-63b1-456f-bd78-4e87d2dd026a" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23515 NE Novelty Hill Road</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span><ix:nonNumeric id="F_3e6b85eb-9914-457e-ae37-c7117ceb5e09" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityAddressAddressLine2" continuedAt="F_3e6b85eb-9914-457e-ae37-c7117ceb5e09_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite </span></ix:nonNumeric></span><span style=""></span></p><div><ix:continuation id="F_3e6b85eb-9914-457e-ae37-c7117ceb5e09_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">B221 #125</span></p></ix:continuation></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c534aeb-c11d-49f9-88d9-7273bfc4d03e" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redmond</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a047fd5-ebd5-4d2a-b75f-7ec46e4f7aad" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">WA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3dfa10a0-c432-484b-911a-305b52faba14" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">98053</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f824fba-b8ba-4822-8c9a-af348d20089b" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">425</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6969faa4-7a01-4354-a222-311baafef2ae" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">276-2300</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Not Applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_049b9660-5f94-481c-97ba-011a729a13be" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0e8e89c-1467-496d-a985-4beea9f3a3a4" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fa5b6fa-9dd7-4760-82a5-204d69d2655a" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a01a2e16-8969-45af-b2bd-394f2729dba8" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6982fb2-f066-473d-aaf4-d7ad7acf72bd" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cafe066-54a6-41f6-8f50-acd0e5cc2ea4" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ELYM</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nasdaq Stock Market LLC</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b7452d3-cfb7-4358-aa2a-5f5bc2f57f17" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nasdaq Global Market</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x2009;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x2009;240.12b-2 of this chapter).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emerging growth company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca762a6d-ec4a-4f91-a136-d5e6ff96aadb" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_047ba4a2-9faa-4588-bee3-ac7b54736766" contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 13, 2021, Eliem Therapeutics, Inc. (the &#x201c;Company&#x201d;) issued a press release announcing its financial results for the quarter ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1.</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.083%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:90.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="elym-20210913ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Press release of Eliem Therapeutics, Inc., dated September 13, 2021</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:83.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.226%;"></td>
    <td style="width:5.025%;"></td>
    <td style="width:3.052%;"></td>
    <td style="width:46.696%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Eliem Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: September 13, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Robert W. Azelby</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Robert W. Azelby</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>elym-20210913ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img212067570_0.jpg" alt="img212067570_0.jpg" style="width:232px;height:123px;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;">Eliem Therapeutics Reports Second Quarter Financial Results</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">SEATTLE and CAMBRIDGE, UK, --(BUSINESS WIRE) &#x2013; September 13, 2021 &#x2013; Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter ended June 30, 2021.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">&#x201c;It has been an exciting year thus far for Eliem, highlighted by our successful initial public offering (IPO) that we completed in August,&#x201d; said Bob Azelby, Eliem&#x2019;s president and chief executive officer. &#x201c;In the second quarter, we continued to advance enrollment on our two Phase 2a studies for ETX-810 in patients with chronic pain conditions. We also made excellent progress toward initiating three clinical studies for ETX-155 in depressive disorders and epilepsy. The proceeds from our IPO, along with the additional capital we raised in our Series B financing in May 2021, are expected to fund our operations through late 2023. We believe this funding will take us through multiple topline clinical data readouts across five different indications and also allows us to advance our preclinical pipeline. We remain committed to developing therapies targeting debilitating disorders that impact tens of millions of people worldwide every day.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Recent Highlights and Upcoming Milestones</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Initial public offering raised $92 million gross proceeds:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">In August 2021, the Company announced the public offering of 7,360,000 shares of common stock, including the exercise in full of the underwriters&#x2019; option to purchase an additional 960,000 shares of common shares, at a public offering price of $12.50 per share. The Company received estimated net proceeds of $83.1 million from the IPO, after deducting underwriting discounts of $6.4 million and estimated offering costs of $2.5 million</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> The IPO was preceded by a Series B financing in May 2021 that raised gross proceeds of $60.0 million.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Program Updates and Milestones</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">ETX-810 in chronic pain:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ETX-810 is a novel new chemical entity prodrug of the bioactive lipid palmitoylethanolamide (PEA) that is currently being evaluated in two Phase 2a clinical trials in patients with diabetic peripheral neuropathic pain (DPNP) and lumbosacral radicular pain (LSRP), commonly referred to as sciatica. ETX-810 was designed to optimize the oral absorption and systemic exposure of PEA, which is believed to play a critical role in the regulation of neuroinflammation and pain signaling in chronic pain.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">ETX-810 in DPNP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">.  The Company is conducting a Phase 2a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the </font></div></div>
  <hr style="page-break-after:always;">
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;visibility:hidden;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">efficacy and safety of ETX-810 in adults with DPNP. The Company expects to have a topline data readout during the first half of 2022.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">ETX-810 in LSRP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">.  The Company is conducting a Phase 2a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of ETX-810 in adults with LSRP. The Company expects to have a topline data readout during the first half of 2022.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">ETX-155 in depression and epilepsy:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">  ETX-155 is a novel GABA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:7.37pt;font-family:Calibri;">A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> receptor positive allosteric modulator that Eliem plans to evaluate in patients with major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizure (FOS). ETX-155 was designed to have broad potency across both synaptic and extrasynaptic GABA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:7.37pt;font-family:Calibri;">A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> receptor subtypes. In Phase 1 clinical studies to date, ETX-155 was shown to be well tolerated with desirable pharmacokinetic properties, including no clinically meaningful food effect and at least a 24-hour half-life to enable once-a-day-dosing. The Company believes these attributes combine to position it well within the GABA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:7.37pt;font-family:Calibri;">A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> PAM therapeutic class.</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">ETX-155 in FOS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">.  The Company expects to initiate a single-arm, proof-of-concept Phase 1b trial in photosensitive epilepsy patients in the second half of 2021 with topline data expected by the first half of 2022.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">ETX-155 in MDD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">. The Company expects to initiate a randomized, placebo-controlled, Phase 2a proof-of-concept trial of ETX-155 in the second half of 2021 with first patient dosed in early 2022 and topline data expected in the first half of 2023. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">ETX-155 in PMD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">.  The Company expects to initiate a randomized, placebo-controlled, Phase 2a proof-of-concept trial of ETX-155 in the second half of 2021 with first patient dosed in early 2022 and topline data expected in the first half of 2023.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Preclinical Pipeline</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">:  The Company is progressing two preclinical programs currently in the discovery stage.</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Kv7.2/3 in pain and epilepsy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">.  The lead preclinical program targets the Kv7.2/3 potassium channel that has been shown to play a role in stabilizing the membrane potential of neuronal cells and controlling neuronal excitability. The Company plans to nominate a clinical candidate in the second half of 2021. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Anxiolytic for generalized anxiety disorder (GAD)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">.  The Company is also in early preclinical development of a novel, rapid-acting, non-sedating, non-addictive anxiolytic for the potential treatment of GAD. The Company plans to nominate a clinical candidate in 2022. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Second Quarter 2021 Financial Results</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Cash Position:  Cash was $99.5 million as of June 30, 2021, as compared to $47.9 million as of March 31, 2021. This does not include an additional $83.1 million in net proceeds from the Company&#x2019;s IPO in August 2021.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Research and Development (R&amp;D) expenses:  R&amp;D expenses were $5.8 million for the three months ended June 30, 2021, compared to $1.4 million for the same period in 2020.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">General and Administrative (G&amp;A) expenses:  G&amp;A expenses were $2.9 million for the three months ended June 30, 2021, compared to $0.2 million for the same period in 2020.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Net loss:  Net loss was $8.7 million for the three months ended June 30, 2021, compared to $1.6 million for the same period in 2020.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">About Eliem Therapeutics, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients&#x2019; quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">https://eliemtx.com/</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">This press release contains forward-looking statements, including, without limitation, statements relating to: Eliem&#x2019;s plans to initiate clinical trials of ETX-155 and the timing thereof; anticipated data readouts of ETX-810 and ETX-155 and the timing thereof; the progression of the Kv7.2/3 and next-generation anxiolytic preclinical programs; the sufficiency of Eliem&#x2019;s current funds and anticipated cash runway through late 2023; and Eliem&#x2019;s commitment to developing therapies targeting debilitating disorders. Words such as &#x201c;on track,&#x201d; &#34;advance,&#x201d; &#x201c;progress,&#x201d; &#x201c;provides,&#x201d; &#x201c;runway,&#x201d; &#x201c;will,&#x201d; &#x201c;enable,&#x201d; &#x201c;expect,&#x201d; &#x201c;believe,&#x201d; &#x201c;plans,&#x201d; &#x201c;initiate,&#x201d; or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Eliem's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the clinical, therapeutic and commercial value of ETX-810, ETX-155 and Eliem&#x2019;s preclinical programs; risks related to the potential failure of ETX-810 and ETX-155 to demonstrate safety and efficacy in clinical testing; Eliem&#x2019;s ability to initiate and conduct clinical trials and studies of ETX-810 and ETX-155 sufficient to achieve a positive completion; the availability of data at the expected times; Eliem's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Eliem's preclinical and clinical development activities; the sufficiency of Eliem's capital and other resources; risks and uncertainties related to Eliem's compliance with applicable legal and regulatory requirements; market competition; changes in economic and business conditions; impacts on Eliem&#x2019;s business due to health pandemics or other contagious outbreaks, such as the current COVID-19 pandemic; and other factors discussed under the caption &#34;Risk Factors&#34; in Eliem's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021. This filing, when available, is available on the SEC's website at www.sec.gov. Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Eliem expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Eliem's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Investors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Chris Brinzey</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Westwicke, an ICR Company</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">chris.brinzey@westwicke.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">339-970-2843</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Media</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Marites Coulter</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Verge Scientific</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Mcoulter@vergescientific.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">415.819.2214</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img212067570_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img212067570_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +C!7H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!<174*S0N'1NA%>;UHZ/JCZ;<C))@<X=?ZCWK*=.^J.W#XIQ?+/8[NBD5E=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTZ\:PU""Y7/R-\P]1W'Y5,X\RL;X>K[*HI=#U&BD!#*&!R",@TM<A] %%%%
M!1110 4444 %%%9NOW?V+0+ZX!PRQ$*?0G@?J132N[$SDHQ<GT/*==OSJ>MW
M=UNRK2$)_NC@?H*SJ**]%*RL?'2DY2<GU"BBBF(**** "BBB@ HHHH ****
M"BBB@#TOP5XB.H6W]G73YN85^1B>9$_Q'^>]==7AEK<S65U%<P.4EC8,I'K7
ML>BZK%K.F17<6 3Q(F?N,.H_SVKCK4^5W1]#EV+]K'V<MU^1H4445@>F%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFD9OR _QK2DKS1RXZ7+AYOR//****[SY4**** "BBB@ HHHH **** "BBB@
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MV4K^8_\ K5I2^-''CU?#2_KJ>=T445WGRX4444 %%%% !1110 4444 %%%%
M!1110 4444 :_AK5CH^M0SL<0O\ NY1_LGO^'!_"O8@00"#D'H:\&KU?P7JG
M]HZ"D;MF:U_=-[C^$_EQ^!KFQ$/M'L957LW2?JCHJ***Y3W HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .2\6Z02?[2@7VF _1OZ5Q%]<_9;<L/OMPOUKV-E5U*L 5(P0>XKQWQ?
M8?9]5E-MEK1&*@?W#W_#/\JZ:,KZ,\?'T%!^TCU.;)))).2:***Z#RPHHHH
M**** "BBB@ HHI55G8*H)8G  [T .BC>:18XU+,QP!77V-HME:K$O)ZL?4U6
MTK3!9IYDF#.P_P"^1Z5I5G)W-X1MJPHHHI&A<TV^?3[U)ER5Z.OJM=\CK)&K
MH058 @CN*\UKK_#%[YUFULYRT)^7_=/_ ->LJL=+G=@JMGR/J;M%%%8'IA11
M10 4444 >/\ BG3_ .SO$-U$%Q'(WFQ_1N?T.1^%8U>D^/\ 2_M.FQZA&OSV
MQVO[H?\  _S->;5WTI<T3Y7&T?95FNCU04445H<H444C.J#+,%'J30 M%5GO
M[=/XBQ_V14#:H/X8B?J: LS0HK*.IS'HB#\Z8=0N#W4?A2'RLV**Q_[0N/[X
M_P"^12C4;@=U/X4!RLUZ*RQJDG\4:'Z<5*NJ1G[T;#Z'- 69?HJ!+R"3I( ?
M1N*G!!&0<BF(**** /1_AY?>=IEQ9,?F@?<O^ZW_ -<'\Z[*O*O ][]D\21Q
MDX2X1HC]>H_48_&O5:X:T;3/I<NJ<]!+MH%%%%9'>%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ_W15>NP^>42W+J$S\+A![=:JLS.<LQ)]2:2B@H**** "BBB@ HHHH ****
M"GI+)&<HY7Z&F44 7XM3<<2J&'J.#5Z*YBF^XPSZ'K6%0#@Y% G$ZBSN&L[V
M"Y3[T4BN/P.:]Q1UD174Y5AD'U%?.4&H21X63YU]>]>[>%+U=0\+Z?<*<CRM
MA^JG;_2N?$+1,];*96E*'S-FBBBN4]L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?.#'<1*H;)[\]?UJK4<\?FQD=QR*'%,*=::>K9U&G^,[:8A+V(P,?XU^9?\
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M 'CTKS\DDDDY)K2E'J<6-J62@@HHHK<\T**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "K&GG;J5JWI,A_457JSIP!U.T!Z&9/_0A2
M>Q4/B1Z'1117(>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBBN4]P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-<U6<*?5G7B,7;W8?>23SRW,IEFD9W/4DU'116QYS=]6%%%%,04444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO?/C?_R)=G_V$4_]%R5X'6]/8]C!?P@HHHJSL"BBB@#ZS\.?\BQI/_7E#_Z
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M325JE8XY.[N.C<QRHXZJ0:ZOJ*Y*NI@.ZWB/J@/Z5$SHPSW1)1114'4%%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWH6'5HDRRCA9@.K+[^H_$<=.[K%JVYY,X2A+ED%%%%(@**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *[;P5X';6]NH:@&33P?E0'!F(_DOO6#X7T4Z]K]O9'(B)WS$=D'7\^G
MXU[[##';PI#"@2.-0J*HP% X KGKU7'W5N>SE6 5=^UJ?"OQ8VVMH+.W2WMH
MDBA085$& *EHHK@/J$DE9!1110,**** "JFJ:E;:/I=SJ-X^RWMT+N?Z#W)X
M'UJW7B/QG\4&XOHO#ML_[JWQ+<X/WG(^5?P!S^/M515W8UH4G5FHGGWB;Q#=
M^)]<GU.[)!<[8X\Y$2#HH_SR23WK(HHKH/>2459!1110,*VO#/A;4O%>IBST
M^+Y1@RS/G9$/4G^0[U6T+1;OQ#K-OIEDN9IFQN/1%[L?8"OI_P .>';'PQHT
M6G6*?*O,DA'S2OW8^_\ (8%1*5CEQ.(]DK+<S?"G@/1_"< -M$)[TC#W<JC>
M?4+_ '1[#\2:ZBBBL&[GCRDY.\F%%%%!(4444 %%%% !6)XC\*:1XIM#!J5L
M&<#$<Z<21_0_T/'M6W10.,G%W1\O^,O!.H>#K\1S_O[.4GR+E5P&]B.S>WY5
MS-?7.K:39:YIDVGW\(EMYEPP/4'L0>Q'8U\P^+/#5SX5U^;3;CYE'SPRXP)(
MST/\P?<&MX2N>OA<3[5<LMS$HHHJSL"IK2[GL;R&[M96BGA</&Z]58<@U#10
M(^I_!OB:'Q7X<@U!-JSC]W<1C^"0=?P/!'L:WZ^=?A3XF.A>*DLYG(L]1(A<
M'HLG\#?F<?1O:OHJN>4;,\3$TO93LM@HHHJ3G"BBB@#S7XW_ /(EV?\ V$4_
M]%R5X'7OGQO_ .1+L_\ L(I_Z+DKP.MZ>Q[&"_A!1115G8%%%% 'UGX<_P"1
M8TG_ *\H?_0!6G69X<_Y%C2?^O*'_P! %:=<K/G9?$PHHHH)"OC^[_X_)_\
MKHW\Z^P*^/[O_C\G_P"NC?SK6GU/1R_>7R(:***U/3"BBB@#VGX%?\>>M_\
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MM_VQ_P#1R5\U5]*_%7_DFVK?]L?_ $<E?-5;4]CUL!_#?K_D%%%%:'<%%%%
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M -"7\J]HKGDK,\+$PY*K04445)@%%%% !14-Q=06D?F3RK&OJ>_T]:Q+CQ7
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M12VURYL78#[7$"F>[)DX_(M^5>N5Y^(3]HSZ_*&GA8I=+_F%%%%8'IA1110
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M_%CZ!11174>&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $MK<S6=U%<V[E)HF#HP[$5[IX5\46WB73_,7$=W
M$ )X?0^H]C7@U:&B:Q<:%JL-_;$[D.&3. Z]U/U_^O656DIKS/0R_&RPU37X
M7O\ YGT114%E=Q7]E!=P-NBF0.I]B,U/7FGV*::N@HHHH&%%%% 'S]\9]0^U
M>-4M V5M+9$*^C-EC^A7\J\ZKH_'UT;SQ[K4I.=MTT7_ 'Q\G_LM<Y71'8]^
MC'EIQ7D%%%%4:A7:_"J*W;QY:SW4L<4=M')+F1@H)V[1U_WL_A7%44FKHB<>
M:+CW/KK^U],_Z"-I_P!_U_QH_M?3/^@C:?\ ?]?\:^1:*S]GYG#_ &>OYCZZ
M_M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&OD6BCV?F']GK^8^NO[7TS_ *"-
MI_W_ %_QH_M?3/\ H(VG_?\ 7_&OD6BCV?F']GK^8^NO[7TS_H(VG_?]?\:/
M[7TS_H(VG_?]?\:^1:*/9^8?V>OYCZZ_M?3/^@C:?]_U_P :/[7TS_H(VG_?
M]?\ &OD6BCV?F']GK^8^NO[7TS_H(VG_ '_7_&C^U],_Z"-I_P!_U_QKY%HH
M]GYA_9Z_F/KK^U],_P"@C:?]_P!?\:/[7TS_ *"-I_W_ %_QKY%HH]GYA_9Z
M_F.V^*R6_P#PGMU/;2Q21W$4<FZ-@1G;M/3_ ':XFBBM$K*QW0CRQ4>P4444
MRPKN/A+?FR^(%I'NVI=1R0-_WSN'ZJ*X>MGPC<FT\8Z-.,X6]BSCT+ ']":3
MV,ZL>:#7D?5M%%%<Q\^%%%% 'FOQO_Y$NS_["*?^BY*\#KWSXW_\B79_]A%/
M_1<E>!UO3V/8P7\(****L[ HHHH ^L_#G_(L:3_UY0_^@"M.LSPY_P BQI/_
M %Y0_P#H K3KE9\[+XF%%%%!(5\?W?\ Q^3_ /71OYU]@5\?W?\ Q^3_ /71
MOYUK3ZGHY?O+Y$-%%%:GIA1110![3\"O^//6_P#KI#_)Z]=KR+X%?\>>M_\
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M5G3I/*U.TDQG9,C8]<,*K5-:?\?D'_71?YT">Q]@4445RGS@4444 >:_&_\
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M++[/XFCN0/EN8%)/JR_*?T"UTX9VG8\?.Z?-04NS.)HHHKN/E0HHHH ****
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M_P"@-_Y-3?\ Q==C11S/N'MJG\S^\X[_ (55X+_Z W_DU-_\71_PJKP7_P!
M;_R:F_\ BZ[&BCF?</;5/YG]YQW_  JKP7_T!O\ R:F_^+H_X55X+_Z W_DU
M-_\ %UV-%',^X>VJ?S/[SCO^%5>"_P#H#?\ DU-_\71_PJKP7_T!O_)J;_XN
MNQHHYGW#VU3^9_><=_PJKP7_ - ;_P FIO\ XNC_ (55X+_Z W_DU-_\778T
M4<S[A[:I_,_O.._X55X+_P"@-_Y-3?\ Q='_  JKP7_T!O\ R:F_^+KL:*.9
M]P]M4_F?WG'?\*J\%_\ 0&_\FIO_ (NC_A57@O\ Z W_ )-3?_%UV-%',^X>
MVJ?S/[SCO^%5>"_^@-_Y-3?_ !='_"JO!?\ T!O_ ":F_P#BZ[&BCF?</;5/
MYG]YS>D> O#.A:C'J&FZ;Y%U&"%?SY&P",'AF(Z&NDHHI7N3*4I.\G<****"
M3COBK_R3;5O^V/\ Z.2OFJOI7XJ_\DVU;_MC_P"CDKYJK:GL>M@/X;]?\@HH
MHK0[@HHHH ^I_ __ "(VB?\ 7G'_ .@UOU@>!_\ D1M$_P"O./\ ]!K?KF>Y
M\]4^-^H4444B HHHH **** "BBB@ KY8\;_\CSK?_7[+_P"A&OJ>OECQO_R/
M.M_]?LO_ *$:TI[G?@/C?H8%%%%;'JA1110!['\!_P#F8/\ MW_]JU['7CGP
M'_YF#_MW_P#:M>QUSS^(\3%_QI?UT"BBBI.8**** "BBB@ HHHH *\<^/'_,
MO_\ ;Q_[2KV.O'/CQ_S+_P#V\?\ M*JA\1TX3^-'^NAXY11170>V%%%% &SX
M1_Y'30O^PC;_ /HQ:^K:^4O"/_(Z:%_V$;?_ -&+7U;6-3<\O,/B04445F>>
M%%%% #)88YXS'*BNAZAAD5D3^&+&4YC,D)]%.1^M;5%--K8B=.$_B1SG_")1
M_P#/XW_?'_UZM6_AFQB(,GF3'T8X'Z5LT4^>7<S6&I+:(R.*.% D2*B#HJC
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M^KQ)F2PDVR8'_+-\#]&V_F:N#LSJP<^6JO,\&HHHK<]H**** .I^'>NKX?\
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M:7]= HHHJ3F"BBB@ HHHH **** "O'/CQ_S+_P#V\?\ M*O8Z\<^/'_,O_\
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M84444""BBB@ HHHH \U^-_\ R)=G_P!A%/\ T7)7@=>^?&__ )$NS_["*?\
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M=5WD%%%%(R"BBB@ HHHH X[XJ_\ )-M6_P"V/_HY*^:J^E?BK_R3;5O^V/\
MZ.2OFJMJ>QZV _AOU_R"BBBM#N"BBB@#ZG\#_P#(C:)_UYQ_^@UOU@>!_P#D
M1M$_Z\X__0:WZYGN?/5/C?J%%%%(@**** "BBB@ HHHH *^6/&__ "/.M_\
M7[+_ .A&OJ>OECQO_P CSK?_ %^R_P#H1K2GN=^ ^-^A@4445L>J%%%% 'L?
MP'_YF#_MW_\ :M>QUXY\!_\ F8/^W?\ ]JU['7//XCQ,7_&E_70****DY@HH
MHH **** "BBB@ KQSX\?\R__ -O'_M*O8Z\<^/'_ #+_ /V\?^TJJ'Q'3A/X
MT?ZZ'CE%%%=![84444 ;/A'_ )'30O\ L(V__HQ:^K:^4O"/_(Z:%_V$;?\
M]&+7U;6-3<\O,/B04445F>>%%%% &;K>H_V?8DH?WTGRI[>I_"N&)))).2>I
M-:_B2Y,^JM&#\D("CZ]3_GVK'KHIQLCQ\54<ZC71!1116AS!7)>*[W?<1V:G
MY8_G?_>/3]/YUU;NL:,['"J,D^U><74[75U+.W61BWTJHHRK2LK$-%%%6<Q;
ML+@Q2^6Q^1_T-:]<[6];R>; C]R.?K31$D24444R0HHHH **** "BBB@ J"Y
MMQ/'CHPZ&IZ*!-75F8+*48JPP1U%)6K=VHF7<N!(/UK+(*D@C!':K3N<LX.+
M$HHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115G3
M[5K[4;:T7.Z>58QCW.*!I-NR/H/2$,>C6,;?>6WC!_!15RD "J% P , 4M>2
M]3] BK)(****0PHHHH **** "BBB@ HHHH **** "D(!!! (/4&EHH YK5?A
M_P"%M8+-<Z1 DA_Y:09B;/K\N,_CFN/U#X&Z9*2=/U:ZM_:9%E'Z;:]5HJE)
MHUC7J1VD>$77P0UV,DVNHZ?,HZ;RZ$_A@C]:R)OA'XPBSLL(9O\ KG<H/_0B
M*^CJ*?M&;K'55V/F9_ACXQ1MIT20G_9FC(_,-3?^%:>,/^@)-_W\3_XJOINB
MG[1E?7ZG9'S7'\*O&<F,Z0$!&<M<Q?RW9K1M_@SXIF(\QK" =_,G)_\ 05-?
M0=%+VC$\=5?8\7LO@7.Q!OM<C0=U@@+9_$D?RKI].^#GA>S(:Y%W?-W$TNU?
MR0#^9KT&BDYLREBJLNI0TW1-+T>/9IVGVUJ,8)BC"D_4]3^-7Z**DP;;U844
M44""BBB@ HHHH **** "BBB@"CJNC:=K=JMMJ=I'=0JXD5)!P& (S^1/YUD?
M\*^\)?\ 0"M/R/\ C72T4[LI3DM$SFO^%?>$O^@%:?D?\:/^%?>$O^@%:?D?
M\:Z6BB['[6?=G-?\*^\)?] *T_(_XT?\*^\)?] *T_(_XUTM%%V'M9]V1P0Q
MVT$<$*!(HU"(HZ* , 5)112("BBB@ KFV\ >%'8LVAVA8G).#_C72447*C*4
M=F<U_P *^\)?] *T_(_XT?\ "OO"7_0"M/R/^-=+13NQ^UGW9S7_  K[PE_T
M K3\C_C1_P *^\)?] *T_(_XUTM%%V'M9]V9VDZ!I6A+*NEV,5JLI!D$8^]C
MI_,UHT44B6VW=A1110(**** "BBB@ HHHH **** (KBV@NX6AN8(YHFZI(@9
M3^!KD=3^%GA/4RS#3S:2'^.T<IC_ (#ROZ5V=%--K8J,Y1^%V/(+[X%PDEM/
MUQT'9+B -_X\"/Y5@77P4\2PDF"YT^=>V)64_JN/UKWZBJYY'1'&55U/FZ7X
M3^,HVPNEI(/5+F+^K"JO_"M/&/\ T!)?^_D?_P 57TW13]HR_K]3LCYE'PS\
M8LP T27)..98Q_[-5J+X3>,I#AM,CBYZO<Q_T8U](44>T8?7ZG9'@5M\$_$D
MI!GNM.@7N#(S,/P"X_6MZQ^!<((;4-<=QW2W@"_^/$G^5>OT4N>1$L96?4XK
M3/A5X3TW:S6#WDB_QW4A?_QT84_E77VMI;64 @M+>*")>D<2!%'X"IJ*EMO<
MPE4E/XG<****1 4444 %%%% !1110 4444 5M0T^TU6QDLKZ!)[:3&^-^C8(
M(_4"L/\ X5]X2_Z 5I^1_P :Z6BG=E*<HZ)G-?\ "OO"7_0"M/R/^-'_  K[
MPE_T K3\C_C72T478_:S[LYK_A7WA+_H!6GY'_&C_A7WA+_H!6GY'_&NEHHN
MP]K/NR&UM8+&TBM;:)8H(E"1HO10.@J:BBD0%%%% !1110 4444 %%%% !6!
M=>"/#-]=RW5SHUM+/*Q>1V!RQ/4]:WZ*+C4G'9G-?\*^\)?] *T_(_XT?\*^
M\)?] *T_(_XUTM%.[*]K/NSFO^%?>$O^@%:?D?\ &C_A7WA+_H!6GY'_ !KI
M:*+L/:S[LS-(\/:3H/G?V7816OG;?,\L?>QG&?S/YUIT44B6VW=A1110(***
M* "BBB@ HHHH *S-7\/:3KWD_P!J6$5UY.[R_,'W<XSC\A^5:=% TVG='-?\
M*^\)?] *T_(_XT?\*^\)?] *T_(_XUTM%.[*]K/NSFO^%?>$O^@%:?D?\:/^
M%?>$O^@%:?D?\:Z6BB[#VL^[.>MO WABTNHKFWT6UCFA<21NH.58'((Y]:Z&
MBBE<ER<MV%%%% @HHHH \\U!B^HW+'J96_G5:K6I(8]3NE/:5ORS56NM;'@3
M^)A1113),S7Y_(T:<@X+@(/QZ_IFN#KK?%TN+2WB_O.6_(?_ %ZY*KCL<U5^
M\%%%%49!6OIQS:_1C616QIRXM ?4DTT3+8M4444R HHHH **** "BBB@ HHH
MH *K75H)AN7B0?K5FB@32:LS!92C%6&".HI*V+BV2=>>&'1JRI87A?:XQZ'L
M:M.YRS@XC****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7;
M?#/2&O?$!OW7]S9KD'U=N /RR?P%<A96=QJ%Y%:6L1DGE;:BCN?\*][\-Z'%
MX>T:*QC(9_ORR ??<]3_ $'L*PQ%3EC;JSU<JPKK5E-_#'\^AK4445YY]:%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q_B>U,6H+< ?+,O
M)_VAQ_+%8=>@:G8KJ%B\)P&^\C>C5P4L3P2M%(I5U."#VKHIRNK'D8NDX3YN
MC&4445H<IRGBYLSVJ]@K']1_A7-UT7BX'[9;G/'EGC\:YVM([')4^)A1113(
M% +$ #)/ K>B3RHD3^Z,5GZ?;%F\YAP/N^YK3IHB3"BBBF2%%%% !1110 44
M44 %%%% !1110 4V2-95*N,BG44",NXLGBRR99/U%5*WZK3V<<V2/E;U%4I=
MS&5+K$R:*FFMI8?O+E?[PZ5#5&+36X444^*&6=PD,;R.>BHI)_2@-QE%;-OX
M3U^Y ,>D7>#T+QE/_0L5?C^'OB:09.GJGING3_&I<XK=FT<+7E\,']S.7HKK
ME^&OB,J"8;=3Z&84UOAQXD5B!:Q,/43K_C2]K#N7]2Q/\C^XY.BNE?P!XG0$
MG3"1_LS1G_V:JTG@[Q%%G=I%R<?W5W?RI\\>Y#PM=;P?W,PZ*TW\.:Y'G=H]
M^ .I^S/C\\5%_8NJ_P#0,O?^_#?X4^9=R'2J+>+^XHT5I1^'M:F/[O2+YN<9
M%N^/Y5J6G@#Q)=L/] \E3_%,ZKC\,Y_2DYQ6[*CAZT_ABW\CF:O:5H]_K5V+
M:PMVE?\ B/14'J3V%>BZ1\*X(F635KPS$=88,JOXL>3^&*[RQT^TTRV6VLK>
M."%>BH,?B?4^]83Q,5\.IZF&R:K-WK>ZOQ,3PGX0MO#5L7)6:^D&))L=!_=7
MT'\_T'2445Q2DY.[/I*5*%*"A!62"BBBD:!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MYC)\;=$BE>,Z9J!*L5.-G;_@5-_X7CH?_0,U#_QS_P"*KG9_@EK<L\D@U/3P
M&8L,E^Y_W:C_ .%':Y_T$]._-_\ XFM;0/2Y,)W.F_X7CH?_ $#-0_\ '/\
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M*5"IS1E;30\OTC_D-6/_ %\1_P#H0KZZKY LIUM;^VN&!*Q2JY ZD @U[?\
M\+QT/_H&:A_XY_\ %5<TWL=>-I3FURJYZA17F=M\:M%NKJ&W73;\-*ZH"=F
M2<?WJ],K)IK<\V=.</B5@HKGO%WBZT\'Z?!>7EO/,DTOE!8<9!P3W(]*Q/#O
MQ5TKQ)KUMI-M87D4UQNVO)MVC:I8YP?1:.5VN-4IN/,EH=Y1112,PHHKE_$?
MQ \/^&6:&[NS+=K_ ,NUN-[CZ]E_$BFE<J,92=HJYU%%>,7OQTF+D6&B1JO9
MIYB2?P '\ZI1_''60W[S2K!E]%+@_GDU7)(Z%@ZW8]THKRO2OC?IEQ(L>J:;
M/9YX\R)Q*H]R, _EFO2--U6PUBR6\TZZBN;=N \;9P?0^A]C4N+6YC4HSI_$
MBY1112,PHHKBO$7Q1\.^'YGMA*]]=IPT5L 0I]&8\#\,D>E-)O8J$)3=HJYV
MM%>)W7QTO68_9-$MXQV\Z9G_ ) 5!%\<M8#YETFQ9?1&=3^>35<DCH^IUNQ[
MG17E^D?&W2+J18]4L)[$GCS$;S4'N< '\@:]'L;^TU.T2[L;F.XMW'RR1MD&
MI::W,9TIT_B19HHHI&84444 %%%% !1110 4444 97B6S-]X=O85&6\O>H]U
M^;^E>-U[SUKQ?7=/.EZU=6F,(KY3_=/(_0UU8>6Z/$S>EK&I\C.HHHKI/&"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I0"Q  ))X '>@ L0 "2> !WK
MTGPEX36P1+^_C!NSS&A_Y9#_ .*_E43FH*[.C#8:=>?+'YLJ^&?!2QA+W5HP
MS]4MVZ+[M[^WYUW(  P.!117#*;D[L^FH4(48\L$%%%%2;!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U?\
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M\@6P_P"O>/\ ]!%?(M?76D?\@6P_Z]X__015U.AVYAM$N4445D>8%>(?'/\
MY#6D_P#7N_\ Z%7M]>'_ !S8?VYI2Y&1;,2/^!?_ %JN'Q'5@_XR(?@=_P C
M/J/_ %Y?^SK7NU>$_ [_ )&?4?\ KR_]G6O=J)_$/&_Q6%<G\2_^2=ZQ_P!<
MT_\ 0UKK*Y/XE_\ ).]8_P"N:?\ H:U,=S"E_$CZH^<=(_Y#5C_U\1_^A"OK
MJOD72/\ D-6/_7Q'_P"A"OKJM*AVYAO$****R/./+_CC_P BQIW_ %^?^R-7
MG7PJ_P"2DZ3_ -MO_1+UZ+\<?^18T[_K\_\ 9&KSKX5?\E)TG_MM_P"B7K:/
MP'JT/]U?HSZ5KR/XZ7[)8Z1IZGY9)))W'NH '_H;5ZY7B'QS_P"0UI/_ %[O
M_P"A5$/B./"*]9'+?#'3UU'X@:8LB@QPLTY^J*2O_CVVOIBOGSX,$#QTP)&3
M9R 9[G*U]!T5-S3'.]2WD%%%%0<04444 %%%% 'DGQ=\$7>H2KXATR%IG2,)
M=1(,M@=' [\<'V ]Z\BTC6=0T+4$OM-NGM[A>-R]"/0CH1[&OKBN2\0_#CPY
MXB=YI[0VUTQR;BU.QB?4C&#^(S6D9V5F=U#%J,>2HM#B-&^..%6/6]+)(ZS6
MC=?^ -_\57:Z=\3_  EJ. -46V<_P7*&/'_ C\OZUY]JGP/U*$LVEZI;W*]0
MDZF-OID9!_2N/U+X?>*M*#-<:-<.@_C@Q*,>ORYQ^-/E@]C7V.&J?"[?UYGT
MW;W5O>0B:VGBGB/1XG#*?Q%2U\BV.I:CH]T9;&[N+293@F)RAX['_ UZAX2^
M,MPDT=GXE598F( O(UPR>[*."/<8/L:3IM;&-3!3BKQU/:J*9%+'/"DT,BR1
M.H9'0Y# ]"#W%/K,X@HHHH **** "BBB@ HHHH **** .<\7>'_[9T_S8%'V
MR $I_MCNO^'_ ->O*B"I((((X(/:O>*X;QGX6\SS-5L$^<<SQ*/O?[0]_7\Z
MZ*-2WNL\C,<'S_O8;]3S^BBBNL\(**** "BBB@ HHHH **** "BBB@"SI]C-
MJ5_#:6XS)*V!Z =R?85[+INGPZ7I\5G ,)&,9[L>Y/UKF_ NB?8[$ZE.G[^X
M&(P?X4_^O_+%=?7'6GS.R/HLMPWLX>TEN_R"BBBL#T@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *IZO_P @6_\ ^O>3_P!!-7*IZO\ \@6__P"O>3_T$T#CN?(M
M?37PT_Y)WH__ %S?_P!#:OF6OIKX:?\ ).]'_P"N;_\ H;5M4V/5Q_\ #7J=
M91116)Y(4444 >+?'7_C]T3_ *YR_P UK,^"'_(Z7G_8.?\ ]&1UI_'7_C]T
M3_KG+_-:S/@A_P CI>?]@Y__ $9'6WV#U8_[I\OU/?****Q/*"BBB@#Y2\7?
M\CIKO_81N/\ T8U>Z_"3_DG=C_UTE_\ 0S7A7B[_ )'37?\ L(W'_HQJ]U^$
MG_).['_KI+_Z&:VG\)ZN+_@1^7Y#/B[8F\\ 7$BC)M9HY\8]]I_1S7@_AS4%
MTKQ+IE^Y(2WN8Y'Q_=##/Z9KZIU&QAU33+JPN!F&YB:)_HPQ^=?)^K:9<:-J
MUUIMVNV>WD*-[^A'L1@CZTJ;TL3@9*4'!GUR"" 000>A%+7GOPL\9PZYHD6D
MW4H&I62! I/,L8X##U(& ?S[UZ%6;5G8\^I!PDXL****1 45Y+\2_B3>:1J4
M>D^'[M8KB$DW4PC5\'L@W CCJ?P'K5;X;>*?&/BKQ)LO-4,FFVR&2X'V:)=V
M>%7(7()//T4U7([7.CZM/V?M'HCV.O._C1_R(T?_ %^Q_P#H+5Z)7G?QH_Y$
M:/\ Z_8__06HCN3A_P"+'U/(OA]_R/VB_P#7P/Y&OJ&OE[X??\C]HO\ U\#^
M1KZAJJFYT8_XUZ!11169PGEWQNU:2U\/V.FQL5%[,S28_B6/!Q^;*?PKRKP3
MH2>(_%UAILV?L[N7FP<?(H+$?CC'XUZ5\=;61['1;L#]U%)+$Q]V"D?^@&N!
M^&^K0Z/XZT^>X<)!(6@=CT&X$ GT&[%;1^'0];#Z8:\=]3Z6@@AM;>.WMXDB
MAC4*B(,!0.@ J2BBL3R0HHKDOB+XFB\-^%;DB0"]NT:&V3/.2,%O^ @Y^N/6
MFE?0J$7.2BCYPU.X%YJUY<@Y$T[R9^K$_P!:^B_A5_R3;2?^VW_HYZ^:J^E?
MA5_R3;2?^VW_ *.>M:FQZF.5J27G_F=C69XC_P"18U;_ *\IO_0#6G69XC_Y
M%C5O^O*;_P! -8H\N/Q(^3*^K_"UZNH^%-*NU.?,M8RWLVT C\P:^4*]J^#7
MBR)[-_#=W*%FC9I+3<<;U/+*/<')_$^E;5%='JXZFY0NNAZY1116)Y 4UW6.
M-I'8*B@EB>@ IU>;_%CQE#I.C2Z':2AM0O$VRA3_ *J(]<^[#@#T)/IEI7=B
MZ=-U)**/#]:O_P"U-=U#4.<7-Q)* >P9B0/UKWWX0Z>UEX!@D8$&[GDGP?3A
M1^B"O!-#TBYU[6K33+529;B0+G&=H[L?8#)_"OJZPLH=.T^VLK==L-O$L2#_
M &5&!_*M*CTL>ACIJ,%!#[F!;JTFMW^[*C(?H1BOD*>"2VN)8)5VR1.4<>A!
MP:^PJ^=OBSX=?1_%TMZB$6FHYF1NP?\ C'USS_P*E3>MC/ 3M)Q?4]A^'>H+
MJ7@+2)%()B@%NP]#'\O\@#^-=17@GPD\91:)J$FC:A*$LKQPT4C'"QR].?0,
M,#/J![U[W4R5F<^)ING4?F%%%%28!17(?$+QBGA/06,$B_VG< I;)@$KZN0>
MP_GBO(]-^(OCS5=2M["TU8O/<2"-!]EAZGN?DZ=ZI0;5SHIX:=2/,M$?1=9G
MB/\ Y%C5O^O*;_T UH0H\<$:22&615 :0@ L<<G X&:CO+9;RQN+5ONS1M&?
MH1C^M28+1GR!7UOH4@F\/Z;*!@/:Q,/Q05\F3P26UQ+;S*5EB<HZGL0<$5]&
M?"S7XM9\&6MOY@-U8*+>5.X ^X?H5Q^(-;5%H>ICXMP4D=M1116)Y05X!\:K
MI9_&D$"D?Z/9HK?[Q9F_D17NVH:A:Z5I\]]>S+#;0J6=V[#^I]N]?*WB+69/
M$'B&]U64%3<2%E4G[JCA1^  %:4UK<[L#!N;EV.\^!W_ ",^H_\ 7E_[.M>[
M5X3\#O\ D9]1_P"O+_V=:]VI3^(C&_Q6%<G\2_\ DG>L?]<T_P#0UKK*Y/XE
M_P#).]8_ZYI_Z&M3'<PI?Q(^J/G'2/\ D-6/_7Q'_P"A"OKJOD"QF%M?VT[=
M(Y5<_@0:^O@00"""#T(K2IT.W,-XBT445D><>7_''_D6-._Z_/\ V1J\Z^%7
M_)2=)_[;?^B7KT7XX_\ (L:=_P!?G_LC5YU\*O\ DI.D_P#;;_T2];1^ ]6A
M_NK]&?2M>0_'2Q9K71[\ [4>2%C[L 5_]!:O7JYSQSX?/B7PE>6$:@W 'FV_
M_71>0/QY'XUG%V9P8>?)44F>#_#?4ETOQ]I<LC;8Y9# W./O@J/U(KZ;KX[_
M 'D,O\4<B-]"I'\C7TQX!\80>+-!C=Y%&HP*$NHN^?[X'H>OUR*NHNIV8^F]
M)HZRBBBLCS0J.2>*(@22HA/3<P%$\\-K;R7%Q*D4,:EG=S@*!U)-?,?CSQ.?
M%?B>>]CW"TC'DVRG^X._U))/XX[548\QT8>@ZSMLCZ<2>&5ML<J.<9PK U)7
ME/P4\/-:Z9=Z[.F&NSY,&>OEJ?F/T+8'_ :]/O8'N;&XMXY7B>6)D61&(9"1
MC((Z$4FK.QG5@H3<4[D]%?*]UXE\56=W-:W&O:NDT+F.13>R?*P."/O5[W\.
M_%,?B?PQ SR[K^U4172L<L2!@/\ \" SGUSZ54H-*YM6PLJ4>:]T=;1114'*
M<_XD\&:+XHMG2^M$%P5PEU&H$J'MSW'L>*^:M=T>?0-<N]+N2&EMI-I8# 8=
M0?Q!!_&OK6OF7XE7T&H?$#59K<J8U=8MP[E$"G]01^%:TV]CT,!.3DX]#T_X
M+:Q+?>&;K3YG+FQF CR>B."0/S#5Z77DGP*M)$T_6;P@^7++%$I]2@8G_P!#
M%>MU$_B.;%)*M*P4445)@%%%% !1110 4444 %%%% !1110!PWBGP9YI>^TJ
M,!^LENH^][K[^WY5P!!4D$$$<$'M7O%<[K_A*SUG=-'BWO/^>@'#?[P_K713
MK6TD>1C,NYWSTM^QY115[4]'OM(G\J\@*9^ZXY5OH:HUU)IZH\.47%VDK,**
M**8@HHHH **** "M;PYI!UG6(K<@^2OSS'_9';\>GXUDUZGX)TC^SM&%Q(N)
M[K#G/4+_  C^OXUG5GRQ.O!8?VU5)[+5G2JJHH50 H& !V%+117 ?4A1110
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MY<T3Y$(O]%U/D3V5];O[H\;#]17H^B?&S5+2%8M7L8K_  ,>=&WE.?J,$'\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K,\1_\BQJW_7E-_Z :TZS/$?_ "+&K?\
M7E-_Z :$5'XD?)E?6?AS_D6-)_Z\H?\ T 5\F5]9^'/^18TG_KRA_P#0!6M0
M]',/AB:=%%%9'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F>(_P#D6-6_
MZ\IO_0#110BH_$CY,KZS\.?\BQI/_7E#_P"@"BBM:AZ.8?#$TZ***R/,"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>elym-20210913_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-09-13T15:44:07.0586+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="elym-20210913.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>elym-20210913.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-09-13T15:44:07.0040+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://eliemtx.com/20210913" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:elym="http://eliemtx.com/20210913" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="elym-20210913_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="elym-20210913_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>elym-20210913_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-09-13T15:44:07.0382+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationExpensesGrossAbstract" xlink:label="us-gaap_HealthCareOrganizationExpensesGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationExpensesGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Expenses, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationExpensesGrossAbstract" xlink:to="us-gaap_HealthCareOrganizationExpensesGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>elym-20210913_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="elym-20210913.xsd" xlink:type="simple"/>
    <context id="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <startDate>2021-09-13</startDate>
            <endDate>2021-09-13</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_27e25d99-be92-4dc7-9c77-44581593cbf9">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_9a430ee6-ce96-4916-93b6-c113941c6753">0001768446</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_7f934b99-6349-40f2-94eb-1dd31b785337">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_bf732ab5-fd0b-48b6-884f-9b74b21d832b">2021-09-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_d9b66dc7-db83-4515-ad19-d51c46661da2">ELIEM THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_829671a8-9a9a-4ebc-bcd5-1474891a374f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_15f0b219-e4ba-43a9-9517-f720f4783543">001-40708</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_01adacdc-9e5a-4233-b110-6d707e674228">83-2273741</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_6e97fb51-63b1-456f-bd78-4e87d2dd026a">23515 NE Novelty Hill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_3e6b85eb-9914-457e-ae37-c7117ceb5e09">Suite B221 #125</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_6c534aeb-c11d-49f9-88d9-7273bfc4d03e">Redmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_4a047fd5-ebd5-4d2a-b75f-7ec46e4f7aad">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_3dfa10a0-c432-484b-911a-305b52faba14">98053</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_2f824fba-b8ba-4822-8c9a-af348d20089b">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_6969faa4-7a01-4354-a222-311baafef2ae">276-2300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_049b9660-5f94-481c-97ba-011a729a13be">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_c0e8e89c-1467-496d-a985-4beea9f3a3a4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_8fa5b6fa-9dd7-4760-82a5-204d69d2655a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_a01a2e16-8969-45af-b2bd-394f2729dba8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_f6982fb2-f066-473d-aaf4-d7ad7acf72bd">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_1cafe066-54a6-41f6-8f50-acd0e5cc2ea4">ELYM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_9b7452d3-cfb7-4358-aa2a-5f5bc2f57f17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_ca762a6d-ec4a-4f91-a136-d5e6ff96aadb">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_9b449378-1ecb-46de-8bf6-881bd9b0d5de"
      id="F_047ba4a2-9faa-4588-bee3-ac7b54736766">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140200176472552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 13,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELIEM THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001768446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2273741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">23515 NE Novelty Hill Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite B221 #125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redmond<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELYM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( (^ +5,D'INBK0   /@!   :
M          "  ?41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( (^ +5-ED'F2&0$  ,\#   3              "  =H2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "04      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="elym-20210913.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="elym-20210913.htm">elym-20210913.htm</File>
    <File>elym-20210913.xsd</File>
    <File>elym-20210913_lab.xml</File>
    <File>elym-20210913_pre.xml</File>
    <File>elym-20210913ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "elym-20210913.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "elym-20210913.htm"
     ]
    },
    "labelLink": {
     "local": [
      "elym-20210913_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "elym-20210913_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "elym-20210913.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "elym",
   "nsuri": "http://eliemtx.com/20210913",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "elym-20210913.htm",
      "contextRef": "C_9b449378-1ecb-46de-8bf6-881bd9b0d5de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "elym-20210913.htm",
      "contextRef": "C_9b449378-1ecb-46de-8bf6-881bd9b0d5de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://eliemtx.com/20210913/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-21-001784-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-21-001784-xbrl.zip
M4$L#!!0    ( (^ +5,^EKAO'A4  "(8 0 1    96QY;2TR,#(Q,#DQ,RYH
M=&WM76U7Z[:6_CS]%1HZO0O6H,3RNP.'NVC(:7-[#K (7>W,ER[9DHGG.'9J
M.T#NKY\MV0D)! @AX3B@=7M;',MZV2^/]I:VM@[_>3N(T37/\BA-/NV0AK:#
M>!*D+$JN/NT<]]K=[LX_CWXX_$^,T<GG[BDZY3?H."BB:WX2Y4&<YJ.,H]W>
MUSW43>(HX>C/GR^^H),T& UX4B",^D4Q;#6;-S<W#19&29[&HP+:RAM!.F@B
MC(]067L[XU2\0">TX*BE:SK!FH>)<4FLEFFV-+MA>Y[VWYK6TK39[]+A.(NN
M^@7:#?:0^ Q:3Q(>QV/T.4IH$D0T1KU)L_O0SZ"!CN,878BO<G3!<YY=<]80
ME?YPV"^ ($"4)/^T,]/W&Z.19E=-XGE>\U:4V2D+M6[]+&;1M*QXE"5U3;.;
MY<NYHL7"HE99M)@M&LUU8+:TT01"%C T/BD/I/_V1''QVJ?YM/CM@_)SXQ-O
M)T6CV\?J):(;@N>"Y9/B29J< NNS*%C\&2NR9C$>\B84Q$E9\JZI8O%'=\TT
MBXPF>9AF RDLHA<6UG2LVS.5X)S/MP[/C:OT^MEZ7&R0*8GR:!&!@)RD^>?7
M+[V@SP<4W^<#X_=$8=(TO(!O=0UK9*:1*$]-G3A/,;HL,?E@E.,K2H?3#T*:
M^[)P]6)!&SP>#Z;E>1SQ07$KE4_HBN818UIWD3W:$:\);W>.?D"'?4X9_!<=
M%E$1\R,7_W;8+/\4/PYX0:7*8_[W*+K^M--.DP*  %\"SW=04#Y]VBGX;=$L
MU:@I:FU6U1[Z*1O+FEATC?)B'/-/.RS*AS$="]GB!SM'A]%M2Q3G6?EGQ!A/
MY)]WPH<B]FGG\U^ZPW6+>1[VN:=CDP4.]@+'P:9IN<3RC, /O1V4T(%HA4>M
M8P M)H#K<TROJN[>%A<\A('\Y?FFZ1F.BPD/?&S:C&/7#VWLNL1GGJ\QB_&=
MHY#&.3]LSO5F<><\:AH:YS8.N&=CTR,V]@P?'@DQ/),$MF,9LYWK)$#G<1MZ
ME]&XFS!^^QL?K]9)#:38L5W3M!_TM#E/THR'/(,9@>='AP(66KD4?&@-29AH
M"67^M)-'@V$LM$#^UL]$9X3@X8F0-6YS!JQKSM=1-C?;AGS,TU$FGR0,MJH1
M2K(M.\+J4RYI-GF*F'@.(YXAV06^$"7:W=_F*73_XZ/)3_.U#X& *9L\ 2YD
MA9C+CNZFLLEW=^^FW62/%)V\F3Q/&FG.D69"QRGAFC,ZT@15DBHUG"B4^ 2@
M2PRHI36TGPY"J ;GT;]YB\#SL#@8T.PJ2G"1#EOE#P(X<9^+*;-%&D;Y14@'
M43QN748#GDO+X"(=T&3RL9\613JHOI=-TCBZ2EHQ#PNAQOF0)I,>W?2C@F/X
M)>"M8<;Q34:'#WOU5*,[1__XD=C:P6%3U NC'M9]S#X-OEUEZ2AA.$CC-&ME
M5S[=U?;E__8.9GZSW7W7W">:O4_V#AXGU4W9U43,:O'L^,PEJ/<?%>$F5*P]
M^3ZBR*@QJS&_AS$'T"S/5@?$\K=EP-!/8S8[-G<)ROU^VKWLG*#>Y?%EIZ<(
M^'("]CKMWR^ZE]U.#QV?GJ#.G^U?CT]_Z:#VV=>OW5ZO>W:JJ#I/57T)JOYQ
MW/NU>_K+Y=GI/CIIM!M(URS3FU!RML=OUB7T&!\K0@ML:YF2D0\X.Z1,K#)-
MF$'NFGN$W=X#=C]OURQBN)]F8!?/M*O!KRA/XXA-RF=E]7<=?TH^5J+V R/-
M?@&YUV&C/:3FUBK/,I#T^>SB*UJD*R^L9Z$G[X2>8?J>AVW#]+"IA3KV3.YC
MPIA!?,>U#,-9R5&?\?XG2ZIR(:6>-)9K014>W%]5V!!(+=,M!5(*I+X_2"TS
MG8+5=-$YO407G?.SB\MZSNR*?X\3[7R4Y2.:%*A(48\'<CN+&"C-$+%VV1Y*
M0U3TN7@URJ(B@J\[MT&?)E=<[*F)UP0F$L7W.O%]&5=;;ED"]R[X,,T*M#MY
MYC2+@<L%XM=B,S23KSG;:SUGB2S3Z$)+Q \=0Z>^A4.F@57A^L*@,$/L^8[I
MZX2YANZORQ(YETO1G7*!>@>5FVF?=J+;HL7@EP$TTF=T/ 8J\*2FG.OQ(?34
MYZ"AQK[</7YK"V:97BH+1EDP3Q/GK@OZ,HO]"[$#=-VVQ18I\UT#FQ:Q,&7$
MP\PB@6G;-F%4?RUVE'N8%_PJRL4.?'$*;]X>&I:B4>=+M_,57?[:N3@^[_Q^
MV6WW]E'WM-UX8X!8JJ_KF;7?SWK:,F[A;N>6@M$E9+.<NR<RB6B.>D,>B+U>
MAJ($=8L<M?L4INYL;U-L5H[LNYX&WF37:#VD\58F34']F"^223HJTHD@B*Z
M(+:T UD<QW2<CHI6&-UR=G 3L:(/Y)/TK#Z 4<5TF/-6SH<T \-R7FQDW2(R
M270@F[1^'>61'\4PU[0FWU>%H!2;;K/)Y@RC81C&3X*:S8*MN1#\D=WOW$0"
M2J8^[-8S 'D#=,%^QNFWEOPW%C\<7/.LB (:5_)1RLU4[4M:08-$BY)%<O28
M6#^#$F\T9:S#-7)USW8(=;%'/8I-[@?8#YB%B>F8KD>HX9CA>LR;;A*D&;AZ
M,K2P5X#(MH&9139NIVS>41*1BB(:J.##++T6]=364SKA,;T!3^X9\P>@8*&"
M*)G>A$P3*]3 K?<P-WV0:8-ZV+.(@T-'UT+3<0W+--8CTY^CF$/;X"G75#XU
MC6!3<S17"6B-!%0CE-& !=CC%@BH;AC8)T3#-G,TA]N.J>ON>@3TDMYVJPC-
M0 )OK:45'&Q==V#*>6Z]:59<G[ E7&5*;)GW*>T"L35P5O1YAOXURJ*<17+/
M8);WWXV8CK5%U 3_?<[HVE-HOZUZT4X'@R@7Q]&0L#E0">.*H5O+T.Y%#W4&
MPS@=\TPAVTO)-V_3H-.TL5 59DV#M]>-&NG""M'4R[#A03#U]P$A16A%Z(T3
M6BU9KF4"68?[;'//"7V+8-OP"38M.\0^ \_8Y*[#=,8TW:;K<9^/&<MXGE?_
M^0+4(35UG77#(A8Z[<!<>,WC8HQ^C<1A_I2R%^S,UF4P^W.10(N%P."V[UK<
MQYY'3! "AV/*#0<'#B%.P'V+:]ZFA*#:\(^2$6?'Q;*]^:NNLM,;0:7H!7*R
M,[<0(P[2"A95)"E-LN69),E2<]2J"Z=^UG6"?B2Z-3=#W:-]=;:Y[C1=RTP0
M6(9)0;X"0A@VO= #768>=G3'\,/ 9)K!UPH";?CS++M,;^JZ(77!V2!-MA_T
MURDE)M5,)V06YC[\RV0ZQ;YCA=CA@6ES,W0H96N5$KF*>9:=9^EU)-*@U)/@
M?QR_Y:;0Q("5H0]:@VC"?EULZZYS/G@^NON[A92\)(3M+J1$K?.]V3:=P4)*
M-*KAP#1T;+HFV#&$4&QHEF_I(?4I,=>*&^=I7M#X?Z.A#(FH)VIXKF89:GON
M8ZY:5W(J(D//,YC:HB&-4>>6!R.1^PZ=A6$4\'PSVQ)J E$3R =4.9@-D)@.
MGMS@@/^*L-'ZG\BHRRQV%]?^CQ]O=8UX!SFZY#$?]M-DLKLJDV+&(R',Z!BD
M7K*AA78WY:;HH:N;H0_.B2O"UEQ=QV[@44Q#PW29KFFN]^I3:L)_%6.IL8%A
MSJQN;(_WNK<Q[]7V;"^DU,0.%<%\AF5BJH-L&(3XE(8\U.FKUSB^I #CYT+V
M:QT?ICLVU@U-VZK3B J&'R?::5J@X^$P!BL"IJ]WP+\/9IQ\!I.49^A4GA;+
M4/58>0G[* K%";'DBC/4$PMAZ O-B^H\N#HS]E*I4&?&-H*0KTM"^@K*+05+
M[3X/OLG\&'0XS-)A%HD 63^]13Z/TQNA8N*ET#SDXM]0&,7"7HUR%(FDT@Q4
MKTA1'@U&<4$3GH[R>(QR6D1Y.)9?5A^D/A"CW+JK\G%D=T<_@0Z@UC093]Z%
M:0R-B^_$"9U(Q"7FK;4I]&J4JBF KQ"HLLQ9PX5Y+.>.&J[O9.&KSA&:HNHG
MSP=Z]KTB;Q9J<V])J5RIN+>J 4*QG=%0Z_ ]--/S/=O6L!5Z)KBD),"> \ZI
M1@AU=(\2PW^U[_%'%A6 5"+">914$9WYP_. ?IK&/@78*0#\:@O7__C1<TSS
MX#MNK+TO(:X/9RLQ!6&?E5,TG$EN=3$"]#5UJYHO[R6U$KFL=HF#VI\O$#BQ
M#2BX/AOX]5/FQT%?>UO0-]"XRUTOP,2T'6QZ-L/4<RUL^IQ3+S2H05^]_]@#
M]R$  4VNOL)4#]9EK*!727"].'LGHVA0">E#W"4FQ42?@=ZY)()3X 7?N"RI
ML/?=2NXZL-<-J>7;(<4>8X"]#MC KDXMK&LFLSVFVY;UZACS\XP+JU?<\2-S
M& MW/3L+0YXI#%:27"_.@JSB8$98G[6#B<FPONOO+8?(95F%R>]6DM>!R50C
M5.<$ -6S/6Q:-,2^[C-L>&:H.[K'?/KJM!GW,+F;YR.>*616\EQ;SKX<F0V.
M37$M[#+(7)6M-3*_/OJI#JO^[_3ZJHV-NC^=C8?TBI?P@VD(76C1^(:.\X/R
M%M7:T&<+9.*#;:[.K,Z6NYT\XVP.,*?W%4A3MMK]!)!LU5,%/_IFH^$^N]M(
MGB]AK:$2\WXEW_<<Q'SLB-:P9F)'5&CV:D%$E^)^[_)"BZ"/@ICF^1MFZ'B"
MHTC6JEO6_N3_PJC>VSY&;V/F%*5I&]"TC H/L19YLK:);KWQ +[:W="!+(5+
M"I<^MGZ=5K=D2 . 3]90P%V QN"7.Y^B3@FEQ));C1C\9EYQK4>\CN7QT/9<
M/?1U'&JVC4W'8)C2T,3,H?!/$#JZ_^HT%Y7'/":Z+\W?VKKV8A$?%+%7I,&W
M?02^);JF\8BC_])$W#Q!0PY*UZ]%YOZM0]_-J*>B\@9N0@AHR 4:6"8%2"!"
MLT-+PS1@&K>"0.>OCR"KC//2UJPM'G2^_,]7I>I*U6M)Y?JHR66?HU.:,_IW
M.76BKS3[Q@OTY4N[CJ94W<E9BO[&,@:(^VLMG1DX"'U'' UWP>+3*;9"RP_T
MT')"XJS+XIML$<N[*1\$00CGY\TN:GJU:/\2ISZ-*]G^SLD&5AO,MF4#J?<^
M8#=A(ER"(W^, GG@$H;S#;QX+F\AN7<:,LH1#(*#F%R)D&08PDW1%U$70W%"
MDN:(\1 H)R_)+(^$:-:"2\[O[C8WT*X "N= YB+1O -Y/&3R$30'FC<4UVR*
M,]9E"(?N8WW)B],?5"[".NZ^GZF^H?:05S L'Y&#36%^0!U;IS;#/# I-D./
M8$H,&S.+VV'HV92R5V>)*9/234;VBQQ8NQS75L>_V4O$ORG!7Q8TPR=@<!_
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MU]&EGV#4:[MMSW:[MM>9>V>]T].>^ZGEGGW^^*OK]ESWX#8>[P19K1/T/OB
MU%W0-F.8TAVZ)LQG ?$IFNE&?T,C%K30@%(T57=)-,42BWL<MO9U4NA!C^IN
MI)+T9+#&D3_F06:O;QWT)UT(VN)BY;1=M^,\W%6I4'_96F:K2[;7MCM>*Y6A
MA6 TF,S:_A>-:'E:TF\[F=KK=KM.5OH@E<0DA&H]Y_O->);UTX812H :MBY.
M$-KC$)SB*5XB]?UM.GJH!%."HR3-!E*1=[M>QTG\E#,>[1RE=J;P\4-/!OT]
M8.$52TBR&[$E%U'&%4QF;:T%7O8M3'>1K:M4=-X]NZ)D%^.^)4D44VPY_W0F
M%C#@+,FT:KKF<N7V/^T87%8M/&Z^:!>G"68A#C/XVC'E04%$U53DHDA,.9=@
M/9LM$@>M%;]W0DR4?U?]4#A=V_7RZ?8.+OT8<EC]@X5,A!\DNC[J+S#M6^5R
MIQY3&N8<ZC5X*A379&D #8:JT6OJKPR>BN4U<YI@03C,NU ].(\ *^IJ,KE?
M#E.\(FH2L>36CTP>C;):+0Z!D/#I"%9?^@?>57I\K*O5Y%6$Q0IVYZ^";Y/U
MD$>QSZJMFM7U&D[G,)R2J*?=?OY5NRU+:[5Z32B^W40++"HM'DAJM08A"Q<Q
M%]FF,8.] P_Y!J;A;LC#ZM5T_*Y:.S#WTU$("X<LR3Z*>@)TE;Y6TX,PA+U:
MYE^P5V.OTK!)^\IFV\\PVWX5LT/X>2?F?,N>LGJ@? VCV>*Y$Q/![XF*C)]P
M^UC^&I8G'*)X^A>)CSXBC.*:[*HQ'<"9K\)@H;@F2^J,1R=KSJHW@I*D)FLS
M'&P$(/':B[DZ2!BLE20U68-M6V4,9KMHP:G!5[&\9EY7:;#VV0I7Q)U&64T6
M_X2&X;0'<5FT8?D^)PT>S;JZ.')* HC)V.H&'FJ"^*81-HAJLC<16''!\)C-
MSH3J\"SNEDOCVCTB?AV[(RDW6#S+=/F6@O7#[,) %+OABT#7#S\+^8YRFBE7
M.+$OH#X[6!/Z$+HO!8],^0'=&C<<U!$7X+AON1:*(;97:ZYO08BRD>""Q\JO
MFEK@'_HD<#C>$ZCTEYF#N29QIGR[%!ZE#G(,7M,P5"0K<ASMIN$PIT5R&IUF
MTBAE8'(<I\W$49'KR:&<-12*(9^4$_G83"*'::N<Q*=FDG@B2Y;#^=Q,.)49
MN!Q+MYE8C#D^':,U+E8]DDK43!H7N%9F+#61AL:N5:E1C:6A0:PY_:JA-"Z4
M+29Y-8;&!:_EQ+)&T;BHM9S(UB@:%[8^2IQK#HV+4,VY>HVC<9%IQ7L!G2I[
MT:B4OFT4IK</FL.+1J)OG,.QUQR:QXO&H?\O'H;W*)K*BX:A!U3.G1(4."G]
MO#C)"]2'^C?=B[\!4$L#!!0    ( (^ +5,[2%=G;!0  .^2   7    96QY
M;2TR,#(Q,#DQ,V5X.3E?,2YH=&WM76MWVS;2_KZ_ B?-=IUS)$47)XXE;\XZ
MB9O7[]:M-TZW^VT/2((B:I)@ ="R\NMW9@!2U"UV;K;<,KU$HD@0,YAYY@)@
M<)38+'WY%W:4"![!W^S(2IN*ER?_Z1X>]@9'3]U7N.&IO^,H4-&<[BR8L?-4
M_/V1%=>V*_-(Y';<[_7_.HE5;KM&?A#C 7PO["3C>BKSKE7%V%U(92ZZB9#3
MQ(X'O='AL/]BM/CC&HAY)M/Y^+W,A&$_B1E[IS*>5VT%REJ5^>:H!SR5TWP<
M0B^$GCQZ>22S*3,Z_/LC^# <#/O/#YX=]/_;[_U63!\QGMK-/WB:9C*RR7@X
M&A;7DZJ?PQ%\@8:Q=]5]H4J5'NMIP/?Z'?QG\&0R2Z0575/P4(P++;HSS0M'
MTLRU%*@T:C)I2$0TB7X-Q 1:PMN \_C#R^^_&SSO3XZ>%@^"]TT6;6?'S=17
M5!,+'B+Q 0\OIUJ5>=1MB,KPV;-.]1\(S#<7HI-4BHR]3P0T(DHK0\/>B4)I
M:]B%"%4>L7^57$/WV0\RYWDH>0HWF#*UY@'S_K/8FBN=\;1)S6 K8]U-^+*Q
MM' M_$/HZ[<3V2_E[<\YLQIZQZQB/+H"017,SA0+@44R!)DMM)IJGAEF$R!@
MFK!87@F\JN(N_ N2'HK"0B,@X(9QD'MZ0AA#[4"GUYM25Z 6-A$L!\:QP8ON
M<)]ET+FD58U6-79&-=X)['$Z9Z'*BE18$8%XL]/SGUFL-'M\.&301"I5SF3.
M@ 20>)#P4(@(E87;#GA$*I^RF;0)$]?26 G?0FZ2#MYX)2/@'GYENLQG?%YK
M6,JM8,/^<%1IP\Z(V4,4L(?O3GX)3U(1V]NIG&-._PZ4[='+BY/C]^]_/"%S
M\?KX[-6[TS=O3SKLEW]V6+>[]^J7B].?3BXNV*^G[TZ>L.^_NQ[V!Z,)^%6%
M%5D MF,PZJ""#!:_K;MC'7::ASU0PMJ6@53SJ6"!5%:$20YD3IUR\WP..AV6
M!E0<U#D25R)5!6IK#J8J15,%S4K@.VI^+DJM<K!GXCH$#0ED*NV<1=(H'0EM
MG"6-R *6>28L/("0 " 1@H)#3UC!90X88.9A(KG5\PX3A4P%7"".*'Q?HT$5
MD[$LA)8%]B2ENU#:\7,N])4J#3-S ]P!LJV* $PT.:- 4%R[G]JYG_1T4!H0
M,NAB L.7XA ZXO!%OWO'58#01NS_RURP4=\QO'<OD/1- >AK:]=-L=G'R/S6
ML=D?#TD< (234\L2;E@@1(Y6FE03%7@N. HUZ$<,'U#""2DZ"[D'$0_F3)6:
MF3(,027B,@5EA<?192T#L("@@3$H'S2W!^;_"5EW-A,-QP"4^[B<EL9V7(>B
M"3-<1NR5"MCQ!Y$&H./T8O?SX01]!6$DCJ73YD2*&+HM0@ O<+#AC3(4NL=J
M G/23>-B2Z^B'=>+'$@MH1<-'U[D6J5IALT#HB%UZ(V? X_ M> P?F54X=G)
M^_]T7PSZ2$/!K81'C/-9FG"%;XF )RHW/?:K -?&*);Q2""K19KBBQ:.OYIQ
M'7DFTC" :R/$(JA8??W@V3-\?220*0;I7Z ?<J>"QQXB_,++BK7*B#88E25O
M"SD%&$S]A=>% -[@RB"S-)?&C1<^=P&C"MUX58$D/ ^_G %\(MA!DQKI*T1H
M'7?C$N$9'E0 QIRXL>ZU$7\" :,-=-A$&GI,4M]2,";\4K!R\5P&F"Q!C*#]
M M5UP:6(6PZ@S2-5(FJ'Y&+&CCLHD,AS@ .XU_4$.47CPM-4S0R]9"$1V.VE
M:$P6 M]'W=4B<X.<9=)Z8AMF<&$ +8"$H"&-!%D^-[X-ZX>Z(<&FAA 4BIRL
ME_>3Z7,A%!([4SJ-9A+E!X)!,)]\WJM4Y^'@7XOU7X;UJV[VQ_CEPC'V?PM_
M!>7]EP)D%B7P#!#"6 4^S<-A:2L^=R<^IULLNC<(S7!^.98?,[;)Z;U_U^>T
M\CF\L4*C]]I',SS/H6LA CD:S!6: 88/.J/GT*U^GYD$K!Q!,Z(_D ]:%%YV
MP+*$:1EY]$?/1(? *;2/X""E55 "] L]TT"8-I5O ]81#1+:D*+4(?D<X),U
M#/+AUG?3!3"\X!6M=;O0$NU8S!Y#//ZLCP&1>\"Y!17M8.,$&$GP&HR5&4=K
ME@N[\!JP@1>CWJ >;W(CD!CG1L08^T#D4X9DVFH*O9T+@;'6M?*\MU\W0FY*
M_<*ZSZ$R_F;H<G7S7<G3I^C'QLCN_H6<1A9S;C-.+C.(M'/8^0W.FW-$O':O
M9.=H[ "UJO%HH]H;X?LK<:._QHUCG#AHLVB?KK#G;C8%/""($X3SAEHG:+=I
MO6^9:83ZS>!^9UV<NK\@WCX7FP/_PT1D%,/"R&+N%8 ]TN6T\DD"J2#ZQ#@Y
ME86,@,04HEH%-(%-R%4*;X&X<^_\Y-BG<J#YL-3:S?8$ BV)N.)IR7UJ9REU
M4@?0?LIS+6T221Y B!PV$[:4,X;;DBJ=LO?F_*?S)Z2T:9D%RD!XCRE:#N%\
MF7+M[_KQXMWYDX[WCE+T;<"OT#[58Y@),;\2\EZ=Q$$S&0D# NAN0E<L SX3
M8Q3EC@,(U9V#AF]W:6/HEK@NE"DU.5C F@Z#L0P3Y(W/95![1<K1]H;H#R$3
MM$K))\3FM9A"UZEE:(-(EGD,[,YX_3HB"[L'8^P,=E,0=\401_*J>KO7<M3F
M\7[OV6CTUPDX@<B&<9R*ZR:$/-\((;^!AR[C.<Z46T0B? IG(K2=$%!T):;M
MQP&(%SZZ$58@PNVZY5/]WFB_/SQ8_'DA\UW-TE[,0;#3FETR)]8$*807MWKP
M(YR[@2&4%X[[P4%M&QHCNMR?.V06#5,D0N52AV.*+*@/GP[?"!^[B=D]MA2-
M(;:JO JF^ )' ;0-9E8!ISLN"=IU$[@=0,$\4HA:48=%"J) E!HPY!V$GU $
MBD0"$]QX1\$!UE*1=I'N8@6?$;,J+">0JC4=),+_'S4^T14'"SZ%UVG!+[L4
M"HYY.N-S Y2UR/"5D>%*&NFF3\>)C,!/NQ^LV"6,N*62"9P>XJ&;+S8\%N %
M@<UM  2/:*Z7/!($B^4<B9O4H/F!A(.CQ.O9A^:D XM*726 8JD-SK&E,;X(
M(NQA;XLJM2K2&L_=-I[H5;?&\S.,YZ?!#K+Y[F!GA\/^-L5QMRF.E>4$57;>
M+R(8[Z;JL\5*B$6VX^WQJ^,[[NZ5T!3:^S%V8]\@XJ W.MA*Q%UW]K:\Q8F#
MPBK-"F4DI89PC80!P)0ARU2$>0M:_<:M7TH(8)F;)0!<2_1D_#>E-RU:87MG
M;]X\Z5 "*!.Y*GAI<#W'0A[WSL_>N.Q/K!!N56X$\$O(#YB!V?OAYXLGO5H>
M5G,Z!)V!5CP"<L"X(QZ[Q2$P6 DS\YP7F'\BH;^VFM=76G'ZRN)DRL#."V%Z
M[#3WUGFPOLP)%]. !'661M0D:D9SI(%@,X$+@U2*BXI@C%T:$49<<S#?K$@X
M]"Y4EX#<E%?4N/P()-$T9VGSQ::-=,XRP7.XBFO98J4BM-Q@>=T2(<M2P0W.
ML [WNPFN"T+[VDUE+$C@<WHK;NSH\F[$Y]T(E":?+IMRGQ3$!3\"YW<M> Q!
MB1,1H<H"-.F8+21MPQ7RUM&(E/EL82N+7T<6SX_/_/HL6O<,0L"-Z;4)S38F
M>Q@QF7?6P.3MIH*MA&2-$,:O;\4P!O$1 BW Z<[ZWCAO%P(?5*$?D2BKC,B]
M+U*O_J_]"[FTVK<1_@S\ M=FV%2O4 WF;:JFA84_%"R ([VKL' S*C13,9N2
M+\UTSH;MM%5JQ;/BHX#@=-[C!P.'S<U<"ZY36@\U)-=O,VSXMM=@8]3;-EO2
MXD:+&[N-&Q!?[RIN_!F H\W1[C*M]YVC/6]L0SKWVY!V4UO':_,QU28WFJ#8
M5N!BL9K,JPBM&Z>-3K0'N0W/6WOZ .SI/Z\.>L.G(Y?YELNS*+NIK]ZZI@)S
MX^N:Z;<O4M*25=05RG+0YS)C8<+SG/;[\\9VXCI1Z]<^5DL>C=O[_Z&:JLQ$
M%H#A%BXI;[T=KJL%X"Y9MTJ[LN24M=U43& YMJAG(G+<Z>8<A)JP$!J4D9^>
MV&+H6S>^A9V'!#O'^;54Z1R3V;A!?"IR7$.-WC"HS[44C6H;;._M\9LG.XU%
M#=^!-F?7SG43G_Q>:[=?/ZZF?W$Q1R&C+J?U'QVXF'?!/^>+;[BGSBUUY\M,
MHVU_-0Y9+;BM&@>.?2[ 4"YQ&YKLL,/;.O=WY]RO5#^D2/.F$HBM(6H-T;WA
M]&LLP7;N9ZHAX*/O.$/_^/!PL6<7M]L >"Y50^K@12H@Y;?D/-X_Z!VN/''&
M=9BPT< 74 +D!4L0*5#S7%D_?[^Z/WIY?S( [](&YGJ_L@?P14T9W"@KE[:%
MMS,_K<;M"+.:I3R,(*W :.A-P_79>_<]SXK)FR>48\R-P.H+_EI]B<V$%NSQ
ML]Z+Q0Y^[_&X,D.NE.BF\F6=96T=-/;O5TT8GKE2:RKR'D^_U:%6AW:$60L=
M>NNB(E*AXP@HE<9BP 6AP-Y;TICC)2WRUU:U:-BP5Y^I1?W>L-6B^Q:,5HL^
M2XM^ K\J5085I/KH7+\7O8,OMR[/OT0O=CC$_.8Q9%L,Y!,9=AS@OIEM17"_
MVJ[ZSQG#!S!Z-Z6'UJO6K+YT2YKHMKN*=Y@W]X_1VZ3:[9/Y4Q5WIKRM$4N/
M@[EF*@Q+S6:)R#T!ADJ7XHQS.G>D(/4:^IG( +]T:(Z,IJX4)A]D%O 4ZX1V
M7"]+[9B&3 :N:2PK1)OR$I4)!;PVTA>"A?<T>,KKNJ)4U6VQ(:$N62IIBP.6
M;"E#NT@OF^8@7<'@1W1?)G!23IJ,.(6)</B9%JZX#3#-E>^-?#=6+TTE'C,A
M,ZRU+Y;N=$.]O)G'+C.VY\'43PD"'^!&])TU/(-<0O=[.N_XHB9N5P^VZMY'
MY>I\^W59O-]+3M($A%1[+>(2)!"9+>*8SHY9U%VE>[KX_ND&8>VQ8TM]"I46
MKO:?Z[ 5/,-!RQ3$ KRQ*ABZE6$!/WA[(M*BV4.&K&()+Z!EW8%'84SC,HVE
MFZ/$7\VNE&;Y<T+E%\^I)=869OST*>[:R>QU#Y#QZ</A[!W*6>MRWI)A/RB-
M5;Z[/RK<F#9E%Q;0!K-X;>VYG:3U_ATYFOF@+;#@3^ 61%>['OPE,L@D3:F7
M)E-+4V./8X=,-48ZJ<RH]+@"5VMQ*S;KZ\VK\5J]_6J6NUYGNUK)K;%JEM:\
M8L@OLZK^N5#Q!*Z#^R +LJO+Y=D;91#PX9L:\A9Y6FT(]FY@M28)'\/#L;IN
M\8,OGU;/\&]:=.C:-"66:)"T*1B[M,P#ORZ1"M+[>O$-@CYZ%M'$D;72'M6+
MI]3]YQ:,!R<2/A@\?"'!&;/JO /E#R9;'*CP_7>C_8FO9M^\ZNZOF+GQ%SIK
M:?T71^OZ=:S3OW[5[8O=<)V60Z]?]SMD-W0()7']<B67BU_ G73A@@'IP:*
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M;2TR,#(Q,#DQ,U]P<F4N>&UL4$L! A0#%     @ CX M4SM(5V=L%   [Y(
M !<              ( !G"0  &5L>6TM,C R,3 Y,3-E>#DY7S$N:'1M4$L%
3!@     %  4 20$  #TY      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
